Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ormat Technologies $1 billion convertible senior notes offering
We advised the representatives of the several initial purchasers on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
Solid Biosciences $240 million private placement
We advised the lead placement agents
Korro Bio $85 million private placement
We advised the placement agents
MiniMed $560 million IPO
The carve-out IPO of Medtronic’s diabetes unit is the second largest medtech IPO ever
Revolution Medicines $1 billion at-the-market offering
We advised the sales agent on the offering
RXO $400 million senior notes offering
We advised the representative of the initial purchasers on the offering
Averin Capital Acquisition $250 million IPO
We advised the underwriters on the IPO
AgomAb Therapeutics $200 million IPO
We advised the representatives of the several underwriters on the IPO